RenovoRx Announces Acceptance of Clinical Data Abstract at the ASCO Gastrointestinal Cancers Symposium 2026

Core Insights - RenovoRx, Inc. has announced the acceptance of its abstract submission for the ASCO Gastrointestinal Cancers Symposium 2026, focusing on its innovative targeted oncology therapies and the RenovoCath drug-delivery device [1][4] Company Overview - RenovoRx is a life sciences company specializing in targeted oncology therapies and has developed the FDA-cleared RenovoCath device for drug delivery [7] - The company aims to address high unmet medical needs in cancer treatment through its patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform [7] Clinical Trial Information - The ongoing Phase III TIGeR-PaC clinical trial evaluates the TAMP therapy platform for treating locally advanced pancreatic cancer (LAPC) [6][10] - A pharmacokinetic and pharmacodynamic sub-study will compare intra-arterial gemcitabine delivered via RenovoCath to standard intravenous chemotherapy [2][3] Presentation Details - The abstract presentation is scheduled for January 9, 2026, at the ASCO GI symposium in San Francisco, with specific time slots for the presentation [4][5] Financial Performance - In the first nine months of 2025, RenovoRx generated approximately $900,000 in revenue from RenovoCath sales, indicating early commercial traction [8] - The company is actively exploring additional revenue-generating activities to meet anticipated demand for its products [9]